MCM Vaccines

Executive Summary

MCM Vaccines is a European joint venture between Sanofi and Merck (MSD), established in 2017 to develop and commercialize a pediatric hexavalent vaccine targeting six major infectious diseases in infants and toddlers. The vaccine combines antigens from both parent companies, leveraging their extensive expertise in vaccines and immunology. While the hexavalent vaccine market is competitive, MCM's product aims to differentiate through improved efficacy, safety, or manufacturing efficiency. The joint venture structure provides strong financial backing and global distribution capabilities, but the company faces regulatory hurdles and intense competition from established hexavalent vaccines such as Sanofi's own Pentacel and other combination vaccines. With no recent public updates, MCM appears to be in a late-stage development or early commercialization phase, with potential catalysts including regulatory submissions or approvals in major markets. The company's success hinges on demonstrating a superior profile and securing timely approvals.

Upcoming Catalysts (preview)

• Q4 2026EMA submission for hexavalent vaccine80% success
• Q3 2026Phase 3 clinical data readout75% success
• Q2 2027FDA pivotal trial initiation65% success